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Sevelamer improves endothelial 
dysfunction in CKD patients
Multiple clinical trials to date have compared calcium-containing 
phosphorus binders with non-calcium-containing phosphorus 
binders with respect to both intermediate and hard clinical 
outcomes. The results are varied and have contributed to the 
signiﬁcant controversy surrounding this topic.
Caglar et al. randomized 50 patients with stage 4 chronic kidney 
disease (CKD) to receive either sevelamer or calcium acetate for 8 
weeks and measured fetuin-A, C-reactive protein, and endothelial 
function before and after the treatment period. The sevelamer 
group had signiﬁcantly increased fetuin-A and improved endothe-
lial function, as measured by ﬂow-mediated dilation (P < 0.001; 
5.7% ± 0.8% to 6.7% ± 0.8%). No diﬀerence in fetuin-A, C-reactive 
protein, or endothelial function was seen in the calcium acetate 
group (5.7% ± 0.4% to 5.7% ± 0.6%).
The conclusions from the trials comparing these two pharma-
cologic methods to bind intestinal phosphorus hinge signiﬁcantly 
on the choice of outcome. The Treat to Goal,1 Renagel in New 
Dialysis (RIND),2 and CARE-2 (ref. 3) studies have all used 
intermediate outcomes with discussion regarding the correlation 
between these intermediate (coronary artery calciﬁcation) and 
hard clinical outcomes. The RIND and Dialysis Clinical Outcome 
Revisited (DCOR)4 studies examined all-cause mortality with 
diﬀerent results; the RIND study demonstrated lower mortality 
among subjects receiving sevelamer, whereas the DCOR study did 
not. This trial adds another piece to this puzzle. Endothelial func-
tion may still not be a validated intermediate outcome. However, 
these data are consistent with previous data on coronary artery 
calciﬁcation. The questions that remain are: What role does the 
reduction in low-density lipoprotein by the use of sevelamer play 
in these diﬀerences? Does the improvement in these intermediate 
outcomes caused by sevelamer confer the same beneﬁt as similar 
reductions caused by the use of statins? And, what is the com-
parative clinical eﬃcacy of sevelamer alone versus calcium acetate 
and a statin combined? (Clin J Am Soc Nephrol 2008; 3: 61–68; 
doi:10.2215/CJN.02810707)
Lynda Szczech
1Kidney Int 2002; 62: 245−252. 2 Block G et al.; Treated with calcium acetate or sevelamer; 
American Society of Nephrology Annual Meeting, San Francisco, California, USA, 1–4 
November 2007; abstr. SU-PO567. 3Kidney Int 2007; 71: 438–441. 4Kidney Int 2007; 72: 
1130–1137.
Suppression of renal-cell carcinoma 
by Notch inhibition
Renal-cell carcinoma (RCC) is treated by nephrectomy. Although 
recent studies showed that treatment with multikinase inhibitors 
signiﬁcantly prolonged survival, eﬀective therapy for patients 
with metastatic advanced-stage RCC is limited. Clear-cell RCC 
(CCRCC), which accounts for approximately 75% of all RCCs, 
is characterized by inactivation of the von Hippel–Lindau (VHL) 
tumor suppressor gene; reintroduction of functional VHL protein 
(pVHL) into VHL-negative CCRCC cells totally suppressed their 
capacity to form tumors in nude mice. Loss of pVHL leads to 
oxygen-independent stabilization of HIF-α and upregulation of 
multiple HIF target genes. Notch signaling is critical for deter-
mination of cell fates within a wide variety of tissues by regulation 
of growth, differentiation, and apoptosis. The known Notch 
receptors (Notch-1 to Notch-4) are transmembrane proteins that 
serve as receptors for the Delta-like (Dll-1, Dll-3, and Dll-4) and 
Jagged (Jagged-1 and Jagged-2) ligands expressed on neighbor-
ing cells. Recent studies show that Notch signaling is important 
during kidney development; Notch inhibition decreased the 
epithelial compartment in the embryonic kidney, particularly 
in the proximal tubules, the tissue from which CCRCCs likely 
arise. Furthermore, targeted mutation of Notch-2 leads to severe 
defects in kidney development. Interestingly, hypoxia attenuates 
diﬀerentiation of cell progenitors in a Notch-dependent manner, 
likely because HIF-1α interacts with Notch-1 and enhances the 
expression of Notch target genes.
Given the role of Notch in renal development and the cross-
talk between Notch and VHL/HIF pathways, Sjölund et al. inves-
tigated Notch signaling in CCRCC. They found that the Notch 
signaling cascade was constitutively active in human CCRCC cell 
lines independently of the VHL/HIF pathway. With the use of 
small interfering RNA targeting the diﬀerent Notch receptors, the 
growth-promoting eﬀects of the Notch signaling pathway were 
attributable to Notch-1, and Notch-1 knockdown was accompanied 
by elevated levels of the negative cell-cycle regulators p21Cip1 and/
or p27Kip1. Importantly, treatment of nude mice with an inhibitor 
of Notch signaling potently inhibited growth of xenotransplanted 
CCRCC cells. Moreover, Notch-1 and the Notch ligand Jagged-1 
were expressed at signiﬁcantly higher levels in CCRCC tumors 
(Figure) than in normal human renal tissue, and the growth of 
primary CCRCC cells was attenuated upon inhibition of Notch 
signaling. These ﬁndings indicate that the Notch cascade may pro-
vide a novel and accessible pathway in the treatment of CCRCC. 
(J Clin Invest 2008; 118: 217–228; doi:10.1172/JCI32086)
Juan Oliver
Immunohistochemical detection of Notch-1 in six CCRCC tumor samples.
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Pioglitazone, cardiovascular 
outcomes, and CKD in patients 
with diabetes and heart disease
The Prospective Pioglitazone Clinical Trial in Macrovascular 
Events (PROactive) compared the effects of the thiazo-
lidinedione pioglitazone and placebo on cardiovascular 
outcomes in subjects with diabetes and macrovascular disease.1 
Although no diﬀerence was found in cardiovascular outcomes 
(P = 0.095) between the two groups, pioglitazone reduced 
all-cause mortality, myocardial infarction, and stroke by 16% 
(P = 0.027). Schneider et al. recently published a secondary 
analysis of the trial focusing on those subjects with CKD 
(glomerular ﬁltration rate < 60 ml/min). Subjects with CKD 
treated with pioglitazone were less likely to have all-cause 
mortality, myocardial infarction, and stroke (hazard ratio 
0.66, 95% conﬁdence interval 0.45–0.98). However, these sub-
jects had a greater decline in renal function (between-group 
diﬀerence in glomerular ﬁltration rate of 0.8 ml/min/y) than 
those with CKD who received placebo.
Secondary analyses of completed trials are valuable to 
generate hypotheses but must be interpreted carefully. The like-
lihood of ﬁnding a diﬀerence in one of the outcomes increases 
with multiple comparisons. Additionally, a potentially greater 
proportion of subjects receiving pioglitazone had albuminuria 
and proteinuria. Although it is tempting to conclude that this 
fact might have aﬀected the greater loss of kidney function in 
that group, we as nephrologists may bring a bias to the inter-
pretation and view all comparisons similarly. These data sug-
gest a potential beneﬁt of pioglitazone to patients with CKD; 
however, this eﬀect, as well as the potential decline in kidney 
function, needs to be explored further. (J Am Soc Nephrol 2008; 
19: 182–187; doi:10.1681/ASN.2007060678)
Lynda Szczech
1Lancet 2005; 366: 1279–1289.
Myeloperoxidase contributes to 
renal failure in mice
Myeloperoxidase (MPO) is a neutrophil-derived enzyme 
with the capacity to catalyze the formation of the proinflam-
matory oxidant HOCl and chlorinating species out of H2O2 
and chloride ions. Apart from MPO’s contribution to innate 
immunity, there is in vitro evidence that it plays a role in 
apoptosis; many studies describe the activation of apoptotic 
pathways in renal ischemia and reperfusion (I/R). Further-
more, inhibition of apoptosis through administration of 
antiapoptotic agents such as insulin-like growth factor-1 or 
ZVAD-fmk (a broad caspase inhibitor) has been shown to 
preserve renal function after I/R.
Matthijsen et al. investigated the role of MPO in a murine 
model of I/R-induced renal failure. They analyzed renal 
function after I/R in MPO-deﬁcient (Mpo–/–) mice and wild-
type (WT) controls. They found a signiﬁcant reduction in 
renal function loss (blood urea nitrogen) after 24 hours of 
reperfusion of ischemically damaged kidneys in Mpo–/– mice 
compared with I/R WT controls (I/R Mpo–/– = 31.3 ± 1.7 
mmol/l versus I/R WT = 42.8 ± 2.1 mmol/l, sham = 7.0 ± 
0.5 mmol/l; P = 0.003). The early reperfusion phase (2 hours 
of reperfusion) was characterized by a substantial increase 
in apoptosis and early complement activation, surprisingly 
similar in Mpo–/– and WT mice. The authors also identi-
ﬁed improved renal function in Mpo–/– mice after extended 
reperfusion and reduced neutrophil inﬂux (P = 0.017) com-
pared with that in WT controls. Activation and deposition 
of complement was not signiﬁcantly reduced in Mpo–/– mice 
compared with WT controls after 24 hours of reperfusion; 
this indicates no speciﬁc in vivo role for MPO in activating 
complement after renal I/R. These results demonstrate that 
MPO contributes to the induction of organ damage after 
renal I/R by inﬂuencing critical factors such as neutrophil 
extravasation but not complement activation. They also pro-
vide evidence that a lack of MPO reduces renal function loss 
after I/R. (Am J Pathol 2007; 171: 1743–1752; doi:10.2353/
ajpath.2007.070184)
Marc De Broe
Similar renal morphology of ischemically damaged WT and knockout 
kidneys after 24 hours of reperfusion.
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